Toward the Establishment of Standardized In Vitro Tests for Lipid-Based Formulations, Part 4: Proposing a New Lipid Formulation Performance Classification System
The Lipid Formulation Classification System Consortium looks to develop standardized in vitro tests and to generate much-needed performance criteria for lipid-based formulations (LBFs). This article highlights the value of performing a second, more stressful digestion test to identify LBFs near a pe...
Saved in:
| Published in | Journal of pharmaceutical sciences Vol. 103; no. 8; pp. 2441 - 2455 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
01.08.2014
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0022-3549 1520-6017 1520-6017 |
| DOI | 10.1002/jps.24067 |
Cover
| Abstract | The Lipid Formulation Classification System Consortium looks to develop standardized in vitro tests and to generate much-needed performance criteria for lipid-based formulations (LBFs). This article highlights the value of performing a second, more stressful digestion test to identify LBFs near a performance threshold and to facilitate lead formulation selection in instances where several LBF prototypes perform adequately under standard digestion conditions (but where further discrimination is necessary). Stressed digestion tests can be designed based on an understanding of the factors that affect LBF performance, including the degree of supersaturation generated on dispersion/digestion. Stresses evaluated included decreasing LBF concentration (↓LBF), increasing bile salt, and decreasing pH. Their capacity to stress LBFs was dependent on LBF composition and drug type: ↓LBF was a stressor to medium-chain glyceride-rich LBFs, but not more hydrophilic surfactant-rich LBFs, whereas decreasing pH stressed tolfenamic acid LBFs, but not fenofibrate LBFs. Lastly, a new Performance Classification System, that is, LBF composition independent, is proposed to promote standardized LBF comparisons, encourage robust LBF development, and facilitate dialogue with the regulatory authorities. This classification system is based on the concept that performance evaluations across three in vitro tests, designed to subject a LBF to progressively more challenging conditions, will enable effective LBF discrimination and performance grading. © 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:2441–2455, 2014 |
|---|---|
| AbstractList | The Lipid Formulation Classification System Consortium looks to develop standardized in vitro tests and to generate much‐needed performance criteria for lipid‐based formulations (LBFs). This article highlights the value of performing a second, more stressful digestion test to identify LBFs near a performance threshold and to facilitate lead formulation selection in instances where several LBF prototypes perform adequately under standard digestion conditions (but where further discrimination is necessary). Stressed digestion tests can be designed based on an understanding of the factors that affect LBF performance, including the degree of supersaturation generated on dispersion/digestion. Stresses evaluated included decreasing LBF concentration (↓LBF), increasing bile salt, and decreasing pH. Their capacity to stress LBFs was dependent on LBF composition and drug type: ↓LBF was a stressor to medium‐chain glyceride‐rich LBFs, but not more hydrophilic surfactant‐rich LBFs, whereas decreasing pH stressed tolfenamic acid LBFs, but not fenofibrate LBFs. Lastly, a new Performance Classification System, that is, LBF composition independent, is proposed to promote standardized LBF comparisons, encourage robust LBF development, and facilitate dialogue with the regulatory authorities. This classification system is based on the concept that performance evaluations across three in vitro tests, designed to subject a LBF to progressively more challenging conditions, will enable effective LBF discrimination and performance grading. © 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:2441–2455, 2014 The Lipid Formulation Classification System Consortium looks to develop standardized in vitro tests and to generate much-needed performance criteria for lipid-based formulations (LBFs). This article highlights the value of performing a second, more stressful digestion test to identify LBFs near a performance threshold and to facilitate lead formulation selection in instances where several LBF prototypes perform adequately under standard digestion conditions (but where further discrimination is necessary). Stressed digestion tests can be designed based on an understanding of the factors that affect LBF performance, including the degree of supersaturation generated on dispersion/digestion. Stresses evaluated included decreasing LBF concentration ([left right arrow with stroke]LBF), increasing bile salt, and decreasing pH. Their capacity to stress LBFs was dependent on LBF composition and drug type: [left right arrow with stroke]LBF was a stressor to medium-chain glyceride-rich LBFs, but not more hydrophilic surfactant-rich LBFs, whereas decreasing pH stressed tolfenamic acid LBFs, but not fenofibrate LBFs. Lastly, a new Performance Classification System, that is, LBF composition independent, is proposed to promote standardized LBF comparisons, encourage robust LBF development, and facilitate dialogue with the regulatory authorities. This classification system is based on the concept that performance evaluations across three in vitro tests, designed to subject a LBF to progressively more challenging conditions, will enable effective LBF discrimination and performance grading. © 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:2441-2455, 2014 [PUBLICATION ABSTRACT] The Lipid Formulation Classification System Consortium looks to develop standardized in vitro tests and to generate much-needed performance criteria for lipid-based formulations (LBFs). This article highlights the value of performing a second, more stressful digestion test to identify LBFs near a performance threshold and to facilitate lead formulation selection in instances where several LBF prototypes perform adequately under standard digestion conditions (but where further discrimination is necessary). Stressed digestion tests can be designed based on an understanding of the factors that affect LBF performance, including the degree of supersaturation generated on dispersion/digestion. Stresses evaluated included decreasing LBF concentration (↓LBF), increasing bile salt, and decreasing pH. Their capacity to stress LBFs was dependent on LBF composition and drug type: ↓LBF was a stressor to medium-chain glyceride-rich LBFs, but not more hydrophilic surfactant-rich LBFs, whereas decreasing pH stressed tolfenamic acid LBFs, but not fenofibrate LBFs. Lastly, a new Performance Classification System, that is, LBF composition independent, is proposed to promote standardized LBF comparisons, encourage robust LBF development, and facilitate dialogue with the regulatory authorities. This classification system is based on the concept that performance evaluations across three in vitro tests, designed to subject a LBF to progressively more challenging conditions, will enable effective LBF discrimination and performance grading.The Lipid Formulation Classification System Consortium looks to develop standardized in vitro tests and to generate much-needed performance criteria for lipid-based formulations (LBFs). This article highlights the value of performing a second, more stressful digestion test to identify LBFs near a performance threshold and to facilitate lead formulation selection in instances where several LBF prototypes perform adequately under standard digestion conditions (but where further discrimination is necessary). Stressed digestion tests can be designed based on an understanding of the factors that affect LBF performance, including the degree of supersaturation generated on dispersion/digestion. Stresses evaluated included decreasing LBF concentration (↓LBF), increasing bile salt, and decreasing pH. Their capacity to stress LBFs was dependent on LBF composition and drug type: ↓LBF was a stressor to medium-chain glyceride-rich LBFs, but not more hydrophilic surfactant-rich LBFs, whereas decreasing pH stressed tolfenamic acid LBFs, but not fenofibrate LBFs. Lastly, a new Performance Classification System, that is, LBF composition independent, is proposed to promote standardized LBF comparisons, encourage robust LBF development, and facilitate dialogue with the regulatory authorities. This classification system is based on the concept that performance evaluations across three in vitro tests, designed to subject a LBF to progressively more challenging conditions, will enable effective LBF discrimination and performance grading. The Lipid Formulation Classification System Consortium looks to develop standardized in vitro tests and to generate much-needed performance criteria for lipid-based formulations (LBFs). This article highlights the value of performing a second, more stressful digestion test to identify LBFs near a performance threshold and to facilitate lead formulation selection in instances where several LBF prototypes perform adequately under standard digestion conditions (but where further discrimination is necessary). Stressed digestion tests can be designed based on an understanding of the factors that affect LBF performance, including the degree of supersaturation generated on dispersion/digestion. Stresses evaluated included decreasing LBF concentration (↓LBF), increasing bile salt, and decreasing pH. Their capacity to stress LBFs was dependent on LBF composition and drug type: ↓LBF was a stressor to medium-chain glyceride-rich LBFs, but not more hydrophilic surfactant-rich LBFs, whereas decreasing pH stressed tolfenamic acid LBFs, but not fenofibrate LBFs. Lastly, a new Performance Classification System, that is, LBF composition independent, is proposed to promote standardized LBF comparisons, encourage robust LBF development, and facilitate dialogue with the regulatory authorities. This classification system is based on the concept that performance evaluations across three in vitro tests, designed to subject a LBF to progressively more challenging conditions, will enable effective LBF discrimination and performance grading. |
| Author | Calderone, Marilyn Jule, Eduardo Pouton, Colin W. Müllertz, Anette Sassene, Philip Blundell, Ross Williams, Hywel D. Vertommen, Jan Porter, Christopher J.H. Kleberg, Karen Benameur, Hassan Igonin, Annabel |
| Author_xml | – sequence: 1 givenname: Hywel D. surname: Williams fullname: Williams, Hywel D. organization: Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia – sequence: 2 givenname: Philip surname: Sassene fullname: Sassene, Philip organization: Department of Pharmaceutics, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen DK-2100 , Denmark – sequence: 3 givenname: Karen surname: Kleberg fullname: Kleberg, Karen organization: Department of Pharmaceutics, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen DK-2100 , Denmark – sequence: 4 givenname: Marilyn surname: Calderone fullname: Calderone, Marilyn organization: Sanofi Research and Development, Montpellier, France – sequence: 5 givenname: Annabel surname: Igonin fullname: Igonin, Annabel organization: Capsugel Product Development Center, Cambridge, Massachusetts – sequence: 6 givenname: Eduardo surname: Jule fullname: Jule, Eduardo organization: Capsugel Product Development Center, Cambridge, Massachusetts – sequence: 7 givenname: Jan surname: Vertommen fullname: Vertommen, Jan organization: Capsugel R&D, Strasbourg, France – sequence: 8 givenname: Ross surname: Blundell fullname: Blundell, Ross organization: Sanofi Research and Development, Montpellier, France – sequence: 9 givenname: Hassan surname: Benameur fullname: Benameur, Hassan organization: Capsugel R&D, Strasbourg, France – sequence: 10 givenname: Anette surname: Müllertz fullname: Müllertz, Anette organization: Department of Pharmaceutics, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen DK-2100 , Denmark – sequence: 11 givenname: Christopher J.H. surname: Porter fullname: Porter, Christopher J.H. email: chris.porter@monash.edu organization: Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia – sequence: 12 givenname: Colin W. surname: Pouton fullname: Pouton, Colin W. email: colin.pouton@monash.edu organization: Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24985238$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kV9v0zAUxS00xLrBA18AWeIFJLL5T9LEvEG1wVAFlVrxajnxDXOV2MF2qMq34ZviLa2EpvHkh_M75_qee4ZOrLOA0EtKLigh7HI7hAuWk3n5BM1owUg2J7Q8QbOksYwXuThFZyFsCSFzUhTP0CnLRVUwXs3Qn43bKa9xvAV8FaKqOxNue7ARuxavo7I6qeY3aHxj8XcTvcMbCDHg1nm8NIPR2UcVknztfD92Khpnwzu8Uj7i_D1eeTe4YOwPrPBX2E2Of1m8Ap-iemUbwItOhWBa00zSeh8i9M_R01Z1AV4c3nO0ub7aLD5ny2-fbhYfllnDRVlmVZsKoByqUgmuCSWU0TknFVDCWZG3tC1JWde10KJoajGnlKkiFSJqTXnF-Tl6M8UO3v0c04qyN6GBrlMW3BgkTTVSUVWEJvT1A3TrRm_T5-6oiok0XCTq1YEa6x60HLzpld_LY_cJuJyAxrsQPLSyMfF-8-iV6SQl8u66Ml1X3l83Od4-cBxDH2MP6TvTwf7_oPyyWh8dfHJAavmXAS9DYyDdRRsPTZTamUfm_AV1lMTp |
| CODEN | JPMSAE |
| CitedBy_id | crossref_primary_10_1007_s11095_015_1843_7 crossref_primary_10_1016_j_xphs_2021_09_009 crossref_primary_10_1016_j_addr_2016_04_007 crossref_primary_10_1016_j_ejpb_2015_07_014 crossref_primary_10_22159_ijpps_2022v14i4_44042 crossref_primary_10_1016_j_xphs_2020_10_055 crossref_primary_10_1016_j_addr_2022_114507 crossref_primary_10_1016_j_jconrel_2023_08_024 crossref_primary_10_1016_j_jddst_2023_104439 crossref_primary_10_2147_DDDT_S292417 crossref_primary_10_1016_j_addr_2019_05_008 crossref_primary_10_1021_acs_molpharmaceut_7b00660 crossref_primary_10_1016_j_apsb_2021_03_025 crossref_primary_10_1016_j_ijpharm_2016_09_032 crossref_primary_10_1021_acs_molpharmaceut_0c00427 crossref_primary_10_1021_acs_molpharmaceut_6b00597 crossref_primary_10_1016_j_addr_2019_01_009 crossref_primary_10_3390_pharmaceutics13081287 crossref_primary_10_1016_j_ejps_2021_105733 crossref_primary_10_1016_j_ejps_2019_104967 crossref_primary_10_1016_j_ejps_2023_106505 crossref_primary_10_1016_j_ijpharm_2017_12_032 crossref_primary_10_1039_C6FO00158K crossref_primary_10_1021_acs_molpharmaceut_7b00442 crossref_primary_10_1208_s12249_017_0785_2 crossref_primary_10_3390_pharmaceutics12040365 crossref_primary_10_1021_acs_molpharmaceut_6b00594 crossref_primary_10_1016_j_ejpb_2017_11_003 crossref_primary_10_1517_17425247_2016_1151872 crossref_primary_10_1016_j_ijpharm_2015_09_009 crossref_primary_10_1021_acs_molpharmaceut_1c00547 crossref_primary_10_1016_j_ejpb_2017_03_001 crossref_primary_10_1186_s41120_023_00086_5 crossref_primary_10_3390_pharmaceutics12010017 crossref_primary_10_1016_j_addr_2019_06_010 crossref_primary_10_1016_j_biochi_2015_11_016 crossref_primary_10_1016_j_ejps_2021_106079 |
| Cites_doi | 10.1016/j.ejps.2006.04.016 10.1007/s11095-006-9194-z 10.1002/jps.21502 10.1211/jpp.58.8.0009 10.1016/j.ejps.2013.04.036 10.1021/mp3006566 10.1208/s12248-014-9672-x 10.1023/A:1016212804288 10.1002/jps.21246 10.1021/jm3006433 10.1007/s11095-013-1038-z 10.1016/j.addr.2007.10.010 10.1002/jps.20039 10.1016/j.ejps.2010.07.005 10.1021/mp300331z 10.1002/jps.21659 10.1002/jps.22217 10.1007/s11095-005-8476-1 10.1016/j.ijpharm.2007.08.057 10.1002/jps.23856 10.1002/jps.23205 10.1016/j.bbalip.2007.02.009 10.1002/jps.10511 10.1021/mp300164u 10.1211/jpp.62.01.0006 10.1007/s11095-007-9363-8 10.1021/mp400035z 10.1002/jps.21451 10.1124/pr.112.005660 10.1146/annurev.me.18.020167.002001 10.1002/jps.22122 10.1016/0166-6622(87)80207-X 10.1023/B:PHAM.0000036914.22132.cc 10.1517/17425247.3.1.97 10.1007/s11095-013-1126-0 10.1016/j.ejpb.2013.10.016 |
| ContentType | Journal Article |
| Copyright | 2014 Wiley Periodicals, Inc. and the American Pharmacists Association 2014 Wiley Periodicals, Inc. and the American Pharmacists Association. Copyright © 2014 Wiley Periodicals, Inc., A Wiley Company |
| Copyright_xml | – notice: 2014 Wiley Periodicals, Inc. and the American Pharmacists Association – notice: 2014 Wiley Periodicals, Inc. and the American Pharmacists Association. – notice: Copyright © 2014 Wiley Periodicals, Inc., A Wiley Company |
| CorporateAuthor | Communicated on Behalf of the LFCS Consortium |
| CorporateAuthor_xml | – name: Communicated on Behalf of the LFCS Consortium |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QO 7QP 7QR 7TK 7U7 8FD C1K FR3 P64 RC3 7X8 |
| DOI | 10.1002/jps.24067 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Biotechnology Research Abstracts Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Neurosciences Abstracts Toxicology Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Genetics Abstracts Biotechnology Research Abstracts Technology Research Database Toxicology Abstracts Chemoreception Abstracts Engineering Research Database Calcium & Calcified Tissue Abstracts Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | Genetics Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1520-6017 |
| EndPage | 2455 |
| ExternalDocumentID | 3383871891 24985238 10_1002_jps_24067 JPS24067 S0022354915304822 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- -~X .3N .GA .GJ .Y3 05W 0R~ 10A 1CY 1L6 1OC 1ZS 31~ 33P 36B 3O- 3WU 4.4 457 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52W 52X 53G 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A03 A8Z AAEVG AAHHS AAIAV AAKUH AALRI AAOIN AAONW AAXUO AAYOK AAZKR ABCQN ABEML ABFRF ABIJN ABJNI ABMAC ABOCM ABPVW ABWRO ACBWZ ACCFJ ACGFO ACGFS ACIWK ACPRK ACSCC ACXME ACXQS ADBBV ADIZJ AEEZP AEFWE AEIMD AENEX AEQDE AEUQT AFBPY AFFNX AFRAH AFTJW AFZJQ AGHFR AI. AITUG AIWBW AJAOE AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS AMBMR AMRAJ ATUGU AZBYB BAFTC BDRZF BFHJK BNHUX BROTX BRXPI BY8 CS3 D-E D-F DCZOG DPXWK DR2 DU5 E3Z EBD EBS EJD EMB EMOBN ESTFP F00 F01 F04 F5P FDB FEDTE G-S G.N GNP GODZA H.T H.X HBH HF~ HHY HHZ HOLLA HVGLF HX~ HZ~ IX1 J0M JPC KQQ L7B LAW LC2 LC3 LH4 LP6 LP7 LSO LW6 M41 M6Q MK0 MK4 N04 N05 N9A NF~ NNB O66 O9- P2P P2X P4D Q.N Q11 QB0 QRW R.K RNS ROL RWI RX1 RYL SSZ SUPJJ SV3 UB1 UKR UNMZH V2E V8K VH1 W8V W99 WBFHL WH7 WIB WJL WQJ WRC WUP WWP WYUIH XG1 XPP XV2 Y6R YCJ ZE2 ZGI ZXP ~IA ~WT AANHP ACRPL ACYXJ ADNMO ADVLN AFJKZ AKRWK OIG AAMMB AAYWO AAYXX ACVFH ADCNI AEFGJ AEUPX AFPUW AGQPQ AGXDD AIDQK AIDYY AIGII AKBMS AKYEP APXCP CITATION EFKBS CGR CUY CVF ECM EIF NPM 7QO 7QP 7QR 7TK 7U7 8FD AGCQF C1K FR3 P64 RC3 7X8 |
| ID | FETCH-LOGICAL-c3977-8f40613e87a93d0101216308e103254f1f707bbb9d95cb96112a50069bd13833 |
| IEDL.DBID | DR2 |
| ISSN | 0022-3549 1520-6017 |
| IngestDate | Sun Sep 28 07:49:38 EDT 2025 Wed Aug 13 09:39:10 EDT 2025 Thu Apr 03 07:05:59 EDT 2025 Thu Apr 24 23:10:57 EDT 2025 Wed Oct 01 02:50:33 EDT 2025 Wed Jan 22 17:01:10 EST 2025 Fri Feb 23 02:31:00 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | lipid-based drug delivery systems precipitation drug solubilization in vitro digestion testing SEDDS bioavailability in vitro models solubility LFCS Consortium supersaturation |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 2014 Wiley Periodicals, Inc. and the American Pharmacists Association. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3977-8f40613e87a93d0101216308e103254f1f707bbb9d95cb96112a50069bd13833 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| PMID | 24985238 |
| PQID | 1548291019 |
| PQPubID | 1006386 |
| PageCount | 15 |
| ParticipantIDs | proquest_miscellaneous_1549198801 proquest_journals_1548291019 pubmed_primary_24985238 crossref_citationtrail_10_1002_jps_24067 crossref_primary_10_1002_jps_24067 wiley_primary_10_1002_jps_24067_JPS24067 elsevier_sciencedirect_doi_10_1002_jps_24067 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | August 2014 |
| PublicationDateYYYYMMDD | 2014-08-01 |
| PublicationDate_xml | – month: 08 year: 2014 text: August 2014 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Washington |
| PublicationTitle | Journal of pharmaceutical sciences |
| PublicationTitleAlternate | J Pharm Sci |
| PublicationYear | 2014 |
| Publisher | Elsevier Inc Elsevier Limited |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier Limited |
| References | Sassene P, Kleberg K, Williams HD, Bakala N'Goma JC, Calderone M, Jannin V, Igonin A, Partheil A, Marchaud D, Jule E, Vertommen J, Maio M, Blundell R, Benameur H, Carriere F, Mullertz A, Porter CJH, Pouton CW. 2013. Toward the establishment of standardized in vitro tests for lipid-based formulations: 6) Effect of varying pancreatin and calcium levels. Submitted AAPS Journal. Amidon, Lennernas, Shah, Crison (bb0065) 1995; 12 Williams, Trevaskis, Charman, Shanker, Charman, Pouton, Porter (bb0145) 2013; 65 Chen, Gudmundsson, Hageman (bb0130) 2012; 55 Tønsberg, Holm, Bisgaard, Jacobsen, Müllertz (bb0195) 2010; 62 Kleberg, Jacobsen, Fatouros, Mullertz (bb0110) 2010; 99 Pouton (bb0010) 2006; 29 Gao, Akrami, Alvarez, Hu, Li, Ma, Surapaneni (bb0190) 2009; 98 Kalantzi, Goumas, Kalioras, Abrahamsson, Dressman, Reppas (bb0080) 2006; 23 Gao, Rush, Pfund, Huang, Bauer, Morozowich, Kuo, Hageman (bb0035) 2003; 92 Yeap, Trevaskis, Quach, Tso, Charman, Porter (bb0170) 2013; 10 Moreno MPdlC, Oth, Deferme, Lammert, Tack, Dressman, Augustijns (bb0085) 2006; 58 Clarysse, Tack, Lammert, Duchateau, Reppas, Augustijns (bb0090) 2009; 98 Kossena, Charman, Wilson, O'Mahony, Lindsay, Hempenstall, Davison, Crowley, Porter (bb0095) 2007; 24 Devraj, Williams, Warren, Mohsin, Porter, Pouton (bb0100) 2013; 49 Pouton, Porter (bb0115) 2008; 60 Yeap, Trevaskis, Porter (bb0165) 2013; 10 Porter, Kaukonen, Taillardat-Bertschinger, Boyd, O'Connor, Edwards, Charman (bb0155) 2004; 93 Hofmann, Small (bb0180) 1967; 18 Butler, Dressman (bb0200) 2010; 99 Cuine, McEvoy, Charman, Pouton, Edwards, Benameur, Porter (bb0015) 2008; 97 Devraj, Williams, Warren, Porter, Pouton (bb0105) 2013; 103 Porter, Kaukonen, Boyd, Edwards, Charman (bb0150) 2004; 21 Gao, Morozowich (bb0120) 2006; 3 Narang, Delmarre, Gao (bb0125) 2007; 345 Fernandez, Jannin, Rodier, Ritter, Mahler, Carriere (bb0025) 2007; 1771 Anby, Williams, McIntosh, Benameur, Edwards, Pouton, Porter (bb0140) 2012; 9 Williams, Sassene, Kleberg, Bakala N'Goma, Calderone, Jannin, Igonin, Partheil, Marchaud, Jule, Vertommen, Maio, Blundell, Benameur, Carriere, Mullertz, Porter, Pouton (bb0045) 2012; 101 Jule (bb0070) 2013 Williams, Anby, Sassene, Kleberg, Bakala N'Goma, Calderone, Jannin, Igonin, Partheil, Marchaud, Jule, Vertommen, Maio, Blundell, Benameur, Carriere, Mullertz, Pouton, Porter (bb0050) 2012; 9 Williams, Sassene, Kleberg, Calderone, Igonin, Jule, Vertommen, Blundell, Benameur, Mullertz, Pouton, Porter (bb0055) 2013; 30 Williams, Anby, McEvoy, Thomas, Vertommen, Blundell, Benameur, Mullertz, Porter, Pouton (bb0075) 2013 Cuine, Charman, Pouton, Edwards, Porter (bb0040) 2007; 24 Igonin, Vertommen, Benameur (bb0030) 2012 Hofmann, Mysels (bb0175) 1987; 30 Mohsin, Long, Pouton (bb0185) 2009; 98 Griffin, Kuentz, Vertzoni, Kostewicz, Fei, Faisal, Stillhart, O'Driscoll, Reppas, Dressman (bb0160) 2013; 86 Williams, Trevaskis, Yeap, Anby, Pouton, Porter (bb0135) 2013; 30 Christiansen, Backensfeld, Weitschies (bb0020) 2010; 41 2007; 345 2004; 21 2010; 99 2012; 101 2013; 49 1987; 30 2012 2013; 65 1995; 12 2006; 58 2013; 86 2013; 103 2006; 3 2008; 97 2012; 55 2010; 41 2010; 62 2009; 98 2003; 92 2004; 93 2006; 23 2013; 10 2007; 1771 2013; 30 1967; 18 2006; 29 2013 2008; 60 2007; 24 2012; 9 Pouton (10.1002/jps.24067_bb0115) 2008; 60 Narang (10.1002/jps.24067_bb0125) 2007; 345 Hofmann (10.1002/jps.24067_bb0180) 1967; 18 Williams (10.1002/jps.24067_bb0145) 2013; 65 Porter (10.1002/jps.24067_bb0150) 2004; 21 Butler (10.1002/jps.24067_bb0200) 2010; 99 Moreno MPdlC (10.1002/jps.24067_bb0085) 2006; 58 Gao (10.1002/jps.24067_bb0120) 2006; 3 Williams (10.1002/jps.24067_bb0135) 2013; 30 Cuine (10.1002/jps.24067_bb0015) 2008; 97 Griffin (10.1002/jps.24067_bb0160) 2013; 86 Yeap (10.1002/jps.24067_bb0165) 2013; 10 Fernandez (10.1002/jps.24067_bb0025) 2007; 1771 Cuine (10.1002/jps.24067_bb0040) 2007; 24 Clarysse (10.1002/jps.24067_bb0090) 2009; 98 Yeap (10.1002/jps.24067_bb0170) 2013; 10 Devraj (10.1002/jps.24067_bb0100) 2013; 49 Kleberg (10.1002/jps.24067_bb0110) 2010; 99 Jule (10.1002/jps.24067_bb0070) 2013 10.1002/jps.24067_bb0060 Christiansen (10.1002/jps.24067_bb0020) 2010; 41 Anby (10.1002/jps.24067_bb0140) 2012; 9 Kalantzi (10.1002/jps.24067_bb0080) 2006; 23 Gao (10.1002/jps.24067_bb0035) 2003; 92 Pouton (10.1002/jps.24067_bb0010) 2006; 29 Williams (10.1002/jps.24067_bb0075) 2013 Hofmann (10.1002/jps.24067_bb0175) 1987; 30 Gao (10.1002/jps.24067_bb0190) 2009; 98 Devraj (10.1002/jps.24067_bb0105) 2013; 103 Chen (10.1002/jps.24067_bb0130) 2012; 55 Porter (10.1002/jps.24067_bb0155) 2004; 93 Amidon (10.1002/jps.24067_bb0065) 1995; 12 Mohsin (10.1002/jps.24067_bb0185) 2009; 98 Williams (10.1002/jps.24067_bb0045) 2012; 101 Williams (10.1002/jps.24067_bb0055) 2013; 30 Williams (10.1002/jps.24067_bb0050) 2012; 9 Kossena (10.1002/jps.24067_bb0095) 2007; 24 Igonin (10.1002/jps.24067_bb0030) 2012 Tønsberg (10.1002/jps.24067_bb0195) 2010; 62 |
| References_xml | – reference: Sassene P, Kleberg K, Williams HD, Bakala N'Goma JC, Calderone M, Jannin V, Igonin A, Partheil A, Marchaud D, Jule E, Vertommen J, Maio M, Blundell R, Benameur H, Carriere F, Mullertz A, Porter CJH, Pouton CW. 2013. Toward the establishment of standardized in vitro tests for lipid-based formulations: 6) Effect of varying pancreatin and calcium levels. Submitted AAPS Journal. – year: 2013 ident: bb0070 article-title: Accelerating lipid-based drug formulation through application of an expert system – volume: 30 start-page: 145 year: 1987 end-page: 173 ident: bb0175 article-title: Bile salts as biological surfactants publication-title: Colloids Surf – volume: 49 start-page: 748 year: 2013 end-page: 760 ident: bb0100 article-title: In vitro assessment of drug-free and fenofibrate-containing lipid formulations using dispersion and digestion testing gives detailed insights into the likely fate of formulations in the intestine publication-title: Eur J Pharm Sci – volume: 24 start-page: 2084 year: 2007 end-page: 2096 ident: bb0095 article-title: Low dose lipid formulations: Effects on gastric emptying and biliary secretion publication-title: Pharm Res – volume: 103 start-page: 1050 year: 2013 end-page: 1060 ident: bb0105 article-title: Choice of nonionic surfactant used to formulate Type IIIA self-emulsifying drug delivery systems has a pronounced influence on the degree of drug supersaturation that develops during in vitro digestion publication-title: J Pharm Sci – volume: 29 start-page: 278 year: 2006 end-page: 287 ident: bb0010 article-title: Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system publication-title: Eur J Pharm Sci – volume: 98 start-page: 1177 year: 2009 end-page: 1192 ident: bb0090 article-title: Postprandial evolution in composition and characteristics of human duodenal fluids in different nutritional states publication-title: J Pharm Sci – volume: 99 start-page: 3522 year: 2010 end-page: 3532 ident: bb0110 article-title: Biorelevant media simulating fed state intestinal fluids: Colloid phase characterization and impact on solubilization capacity publication-title: J Pharm Sci – volume: 12 start-page: 413 year: 1995 end-page: 420 ident: bb0065 article-title: A theoretical basis for a biopharmaceutic drug classification—The correlation of in-vitro drug product dissolution and in-vivo bioavailability publication-title: Pharm Res – volume: 3 start-page: 97 year: 2006 end-page: 110 ident: bb0120 article-title: Development of supersaturatable self-emulsifying drug delivery system formulations for improving the oral absorption of poorly soluble drugs publication-title: Expert Opin Drug Deliv – volume: 10 start-page: 2601 year: 2013 end-page: 2615 ident: bb0165 article-title: The supersaturation tendency of drugs during intestinal processing of lipid-based formulations is greater for basic than neutral/acidic drugs publication-title: Mol Pharm – volume: 10 start-page: 1874 year: 2013 end-page: 1889 ident: bb0170 article-title: Intestinal bile secretion promotes drug absorption from lipid colloidal phases via induction of supersaturation publication-title: Mol Pharm – volume: 92 start-page: 2386 year: 2003 end-page: 2398 ident: bb0035 article-title: Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability publication-title: J Pharm Sci – volume: 30 start-page: 3059 year: 2013 end-page: 3076 ident: bb0055 article-title: Toward the establishment of standardized in vitro tests for lipid-based formulations, part 3: Understanding supersaturation versus precipitation potential during the in vitro digestion of type I, II, IIIA, IIIB and IV lipid-based formulations publication-title: Pharm Res – volume: 24 start-page: 748 year: 2007 end-page: 757 ident: bb0040 article-title: Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs publication-title: Pharm Res – volume: 58 start-page: 1079 year: 2006 end-page: 1089 ident: bb0085 article-title: Characterization of fasted-state human intestinal fluids collected from duodenum and jejunum publication-title: J Pharm Pharmacol – volume: 21 start-page: 1405 year: 2004 end-page: 1412 ident: bb0150 article-title: Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation publication-title: Pharm Res – volume: 101 start-page: 3360 year: 2012 end-page: 3380 ident: bb0045 article-title: Toward the establishment of standardized in vitro tests for lipid-based formulations: 1) Method parameterization and comparison of in vitro digestion profiles across a range of representative formulations publication-title: J Pharm Sci – year: 2013 ident: bb0075 article-title: The LFCS Consortium—(1) In vitro dispersion tests are an effective first screen during lipid-based formulation development and evaluation – volume: 98 start-page: 516 year: 2009 end-page: 528 ident: bb0190 article-title: Characterization and optimization of AMG 517 supersaturatable self-emulsifying drug delivery system (S-SEDDS) for improved oral absorption publication-title: J Pharm Sci – volume: 98 start-page: 3582 year: 2009 end-page: 3595 ident: bb0185 article-title: Design of lipid-based formulations for oral administration of poorly water-soluble drugs: Precipitation of drug after dispersion of formulations in aqueous solution publication-title: J Pharm Sci – volume: 41 start-page: 376 year: 2010 end-page: 382 ident: bb0020 article-title: Effects of non-ionic surfactants on in vitro triglyceride digestion and their susceptibility to digestion by pancreatic enzymes publication-title: Eur J Pharm Sci – volume: 62 start-page: 63 year: 2010 end-page: 70 ident: bb0195 article-title: Effects of polysorbate 80 on the in-vitro precipitation and oral bioavailability of halofantrine from polyethylene glycol 400 formulations in rats publication-title: J Pharm Pharmacol – volume: 18 start-page: 333 year: 1967 end-page: 376 ident: bb0180 article-title: Detergent properties of bile salts: Correlation with physiological function publication-title: Ann Rev Med – volume: 86 start-page: 427 year: 2013 end-page: 437 ident: bb0160 article-title: Comparison of publication-title: Eur J Pharm Biopharm – year: 2012 ident: bb0030 article-title: Physical and Biological Parameters of Poorly Bioavailable Compounds That Influence the Development of Lipid-Based Oral Drug Delivery Systems publication-title: Annual meeting of the Academy of the American Pharmaceutical Scientists – volume: 65 start-page: 315 year: 2013 end-page: 499 ident: bb0145 article-title: Strategies to address low drug solubility in discovery and development publication-title: Pharm Rev – volume: 23 start-page: 165 year: 2006 end-page: 176 ident: bb0080 article-title: Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies publication-title: Pharm Res – volume: 60 start-page: 625 year: 2008 end-page: 637 ident: bb0115 article-title: Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies publication-title: Adv Drug Deliv Rev – volume: 99 start-page: 4940 year: 2010 end-page: 4954 ident: bb0200 article-title: The developability classification system: Application of biopharmaceutics concepts to formulation development publication-title: J Pharm Sci – volume: 1771 start-page: 633 year: 2007 end-page: 640 ident: bb0025 article-title: Comparative study on digestive lipase activities on the self emulsifying excipient Labrasol (R), medium chain glycerides and PEG esters publication-title: Biochim Biophys Acta – volume: 93 start-page: 1110 year: 2004 end-page: 1121 ident: bb0155 article-title: Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: Studies with halofantrine publication-title: J Pharm Sci – volume: 97 start-page: 995 year: 2008 end-page: 1012 ident: bb0015 article-title: Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs publication-title: J Pharm Sci – volume: 9 start-page: 2063 year: 2012 end-page: 2079 ident: bb0140 article-title: Lipid digestion as a trigger for supersaturation: In vitro and in vivo evaluation of the utility of polymeric precipitation inhibitors in self emulsifying drug delivery systems publication-title: Mol Pharm – volume: 9 start-page: 3286 year: 2012 end-page: 3300 ident: bb0050 article-title: Toward the establishment of standardized in vitro tests for lipid-based formulations: 2) The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB and IV formulations during in vitro digestion publication-title: Mol Pharm – volume: 345 start-page: 9 year: 2007 end-page: 25 ident: bb0125 article-title: Stable drug encapsulation in micelles and microemulsions publication-title: Int J Pharm – volume: 30 start-page: 2979 year: 2013 end-page: 2992 ident: bb0135 article-title: Lipid-based formulations and drug supersaturation: Harnessing the unique benefits of the lipid digestion/absorption pathway publication-title: Pharm Res – volume: 55 start-page: 7945 year: 2012 end-page: 7956 ident: bb0130 article-title: Application of lipid-based formulations in drug discovery publication-title: J Med Chem – volume: 30 start-page: 2979 issue: 12 year: 2013 end-page: 2992 article-title: Lipid‐based formulations and drug supersaturation: Harnessing the unique benefits of the lipid digestion/absorption pathway publication-title: Pharm Res – volume: 103 start-page: 1050 issue: 4 year: 2013 end-page: 1060 article-title: Choice of nonionic surfactant used to formulate ype III self‐emulsifying drug delivery systems has a pronounced influence on the degree of drug supersaturation that develops during in vitro digestion publication-title: J Pharm Sci – volume: 12 start-page: 413 issue: 3 year: 1995 end-page: 420 article-title: A theoretical basis for a biopharmaceutic drug classification—The correlation of in‐vitro drug product dissolution and in‐vivo bioavailability publication-title: Pharm Res – volume: 24 start-page: 748 issue: 4 year: 2007 end-page: 757 article-title: Increasing the proportional content of surfactant ( remophor ) relative to lipid in self‐emulsifying lipid‐based formulations of danazol reduces oral bioavailability in beagle dogs publication-title: Pharm Res – volume: 24 start-page: 2084 issue: 11 year: 2007 end-page: 2096 article-title: Low dose lipid formulations: Effects on gastric emptying and biliary secretion publication-title: Pharm Res – volume: 49 start-page: 748 issue: 4 year: 2013 end-page: 760 article-title: In vitro assessment of drug‐free and fenofibrate‐containing lipid formulations using dispersion and digestion testing gives detailed insights into the likely fate of formulations in the intestine publication-title: Eur J Pharm Sci – volume: 30 start-page: 145 issue: 1 year: 1987 end-page: 173 article-title: Bile salts as biological surfactants publication-title: Colloids Surf – volume: 62 start-page: 63 issue: 1 year: 2010 end-page: 70 article-title: Effects of polysorbate 80 on the in‐vitro precipitation and oral bioavailability of halofantrine from polyethylene glycol 400 formulations in rats publication-title: J Pharm Pharmacol – volume: 23 start-page: 165 issue: 1 year: 2006 end-page: 176 article-title: Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies publication-title: Pharm Res – volume: 101 start-page: 3360 issue: 9 year: 2012 end-page: 3380 article-title: Toward the establishment of standardized in vitro tests for lipid‐based formulations: 1) Method parameterization and comparison of in vitro digestion profiles across a range of representative formulations publication-title: J Pharm Sci – volume: 99 start-page: 4940 issue: 12 year: 2010 end-page: 4954 article-title: The developability classification system: Application of biopharmaceutics concepts to formulation development publication-title: J Pharm Sci – volume: 345 start-page: 9 issue: 1 year: 2007 end-page: 25 article-title: Stable drug encapsulation in micelles and microemulsions publication-title: Int J Pharm – volume: 99 start-page: 3522 issue: 8 year: 2010 end-page: 3532 article-title: Biorelevant media simulating fed state intestinal fluids: Colloid phase characterization and impact on solubilization capacity publication-title: J Pharm Sci – volume: 93 start-page: 1110 issue: 5 year: 2004 end-page: 1121 article-title: Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride‐based oral lipid formulations of poorly water‐soluble drugs: Studies with halofantrine publication-title: J Pharm Sci – volume: 92 start-page: 2386 issue: 12 year: 2003 end-page: 2398 article-title: Development of a supersaturable ( ‐ ) formulation of paclitaxel with improved oral bioavailability publication-title: J Pharm Sci – volume: 30 start-page: 3059 issue: 12 year: 2013 end-page: 3076 article-title: Toward the establishment of standardized in vitro tests for lipid‐based formulations, part 3: Understanding supersaturation versus precipitation potential during the in vitro digestion of type I, II, III , III and IV lipid‐based formulations publication-title: Pharm Res – volume: 1771 start-page: 633 issue: 5 year: 2007 end-page: 640 article-title: Comparative study on digestive lipase activities on the self emulsifying excipient abrasol ( ), medium chain glycerides and esters publication-title: Biochim Biophys Acta – volume: 60 start-page: 625 issue: 6 year: 2008 end-page: 637 article-title: Formulation of lipid‐based delivery systems for oral administration: Materials, methods and strategies publication-title: Adv Drug Deliv Rev – year: 2012 – volume: 98 start-page: 1177 issue: 3 year: 2009 end-page: 1192 article-title: Postprandial evolution in composition and characteristics of human duodenal fluids in different nutritional states publication-title: J Pharm Sci – volume: 86 start-page: 427 issue: 3 year: 2013 end-page: 437 article-title: Comparison of tests at various levels of complexity for the prediction of performance of lipid‐based formulations: Case studies with fenofibrate publication-title: Eur J Pharm Biopharm – volume: 55 start-page: 7945 year: 2012 end-page: 7956 article-title: Application of lipid‐based formulations in drug discovery publication-title: J Med Chem – volume: 58 start-page: 1079 issue: 8 year: 2006 end-page: 1089 article-title: Characterization of fasted‐state human intestinal fluids collected from duodenum and jejunum publication-title: J Pharm Pharmacol – volume: 9 start-page: 2063 year: 2012 end-page: 2079 article-title: Lipid digestion as a trigger for supersaturation: In vitro and in vivo evaluation of the utility of polymeric precipitation inhibitors in self emulsifying drug delivery systems publication-title: Mol Pharm – volume: 65 start-page: 315 issue: 1 year: 2013 end-page: 499 article-title: Strategies to address low drug solubility in discovery and development publication-title: Pharm Rev – volume: 18 start-page: 333 issue: 1 year: 1967 end-page: 376 article-title: Detergent properties of bile salts: Correlation with physiological function publication-title: Ann Rev Med – volume: 3 start-page: 97 issue: 1 year: 2006 end-page: 110 article-title: Development of supersaturatable self‐emulsifying drug delivery system formulations for improving the oral absorption of poorly soluble drugs publication-title: Expert Opin Drug Deliv – volume: 97 start-page: 995 issue: 2 year: 2008 end-page: 1012 article-title: Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self‐emulsifying formulations to dogs publication-title: J Pharm Sci – volume: 9 start-page: 3286 issue: 11 year: 2012 end-page: 3300 article-title: Toward the establishment of standardized in vitro tests for lipid‐based formulations: 2) The effect of bile salt concentration and drug loading on the performance of type I, II, III , III and IV formulations during in vitro digestion publication-title: Mol Pharm – volume: 98 start-page: 516 issue: 2 year: 2009 end-page: 528 article-title: Characterization and optimization of 517 supersaturatable self‐emulsifying drug delivery system ( ‐ ) for improved oral absorption publication-title: J Pharm Sci – volume: 10 start-page: 1874 issue: 5 year: 2013 end-page: 1889 article-title: Intestinal bile secretion promotes drug absorption from lipid colloidal phases via induction of supersaturation publication-title: Mol Pharm – volume: 98 start-page: 3582 issue: 10 year: 2009 end-page: 3595 article-title: Design of lipid‐based formulations for oral administration of poorly water‐soluble drugs: Precipitation of drug after dispersion of formulations in aqueous solution publication-title: J Pharm Sci – volume: 41 start-page: 376 issue: 2 year: 2010 end-page: 382 article-title: Effects of non‐ionic surfactants on in vitro triglyceride digestion and their susceptibility to digestion by pancreatic enzymes publication-title: Eur J Pharm Sci – volume: 29 start-page: 278 issue: 3–4 year: 2006 end-page: 287 article-title: Formulation of poorly water‐soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system publication-title: Eur J Pharm Sci – year: 2013 article-title: Toward the establishment of standardized in vitro tests for lipid‐based formulations: 6) Effect of varying pancreatin and calcium levels – volume: 10 start-page: 2601 issue: 7 year: 2013 end-page: 2615 article-title: The supersaturation tendency of drugs during intestinal processing of lipid‐based formulations is greater for basic than neutral/acidic drugs publication-title: Mol Pharm – volume: 21 start-page: 1405 issue: 8 year: 2004 end-page: 1412 article-title: Susceptibility to lipase‐mediated digestion reduces the oral bioavailability of danazol after administration as a medium‐chain lipid‐based microemulsion formulation publication-title: Pharm Res – year: 2013 – year: 2012 ident: 10.1002/jps.24067_bb0030 article-title: Physical and Biological Parameters of Poorly Bioavailable Compounds That Influence the Development of Lipid-Based Oral Drug Delivery Systems – volume: 29 start-page: 278 issue: 3–4 year: 2006 ident: 10.1002/jps.24067_bb0010 article-title: Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system publication-title: Eur J Pharm Sci doi: 10.1016/j.ejps.2006.04.016 – volume: 24 start-page: 748 issue: 4 year: 2007 ident: 10.1002/jps.24067_bb0040 article-title: Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs publication-title: Pharm Res doi: 10.1007/s11095-006-9194-z – volume: 98 start-page: 1177 issue: 3 year: 2009 ident: 10.1002/jps.24067_bb0090 article-title: Postprandial evolution in composition and characteristics of human duodenal fluids in different nutritional states publication-title: J Pharm Sci doi: 10.1002/jps.21502 – volume: 58 start-page: 1079 issue: 8 year: 2006 ident: 10.1002/jps.24067_bb0085 article-title: Characterization of fasted-state human intestinal fluids collected from duodenum and jejunum publication-title: J Pharm Pharmacol doi: 10.1211/jpp.58.8.0009 – volume: 49 start-page: 748 issue: 4 year: 2013 ident: 10.1002/jps.24067_bb0100 article-title: In vitro assessment of drug-free and fenofibrate-containing lipid formulations using dispersion and digestion testing gives detailed insights into the likely fate of formulations in the intestine publication-title: Eur J Pharm Sci doi: 10.1016/j.ejps.2013.04.036 – volume: 10 start-page: 1874 issue: 5 year: 2013 ident: 10.1002/jps.24067_bb0170 article-title: Intestinal bile secretion promotes drug absorption from lipid colloidal phases via induction of supersaturation publication-title: Mol Pharm doi: 10.1021/mp3006566 – ident: 10.1002/jps.24067_bb0060 doi: 10.1208/s12248-014-9672-x – volume: 12 start-page: 413 issue: 3 year: 1995 ident: 10.1002/jps.24067_bb0065 article-title: A theoretical basis for a biopharmaceutic drug classification—The correlation of in-vitro drug product dissolution and in-vivo bioavailability publication-title: Pharm Res doi: 10.1023/A:1016212804288 – volume: 97 start-page: 995 issue: 2 year: 2008 ident: 10.1002/jps.24067_bb0015 article-title: Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs publication-title: J Pharm Sci doi: 10.1002/jps.21246 – volume: 55 start-page: 7945 year: 2012 ident: 10.1002/jps.24067_bb0130 article-title: Application of lipid-based formulations in drug discovery publication-title: J Med Chem doi: 10.1021/jm3006433 – volume: 30 start-page: 3059 issue: 12 year: 2013 ident: 10.1002/jps.24067_bb0055 article-title: Toward the establishment of standardized in vitro tests for lipid-based formulations, part 3: Understanding supersaturation versus precipitation potential during the in vitro digestion of type I, II, IIIA, IIIB and IV lipid-based formulations publication-title: Pharm Res doi: 10.1007/s11095-013-1038-z – volume: 60 start-page: 625 issue: 6 year: 2008 ident: 10.1002/jps.24067_bb0115 article-title: Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2007.10.010 – volume: 93 start-page: 1110 issue: 5 year: 2004 ident: 10.1002/jps.24067_bb0155 article-title: Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: Studies with halofantrine publication-title: J Pharm Sci doi: 10.1002/jps.20039 – volume: 41 start-page: 376 issue: 2 year: 2010 ident: 10.1002/jps.24067_bb0020 article-title: Effects of non-ionic surfactants on in vitro triglyceride digestion and their susceptibility to digestion by pancreatic enzymes publication-title: Eur J Pharm Sci doi: 10.1016/j.ejps.2010.07.005 – volume: 9 start-page: 3286 issue: 11 year: 2012 ident: 10.1002/jps.24067_bb0050 article-title: Toward the establishment of standardized in vitro tests for lipid-based formulations: 2) The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB and IV formulations during in vitro digestion publication-title: Mol Pharm doi: 10.1021/mp300331z – volume: 98 start-page: 3582 issue: 10 year: 2009 ident: 10.1002/jps.24067_bb0185 article-title: Design of lipid-based formulations for oral administration of poorly water-soluble drugs: Precipitation of drug after dispersion of formulations in aqueous solution publication-title: J Pharm Sci doi: 10.1002/jps.21659 – volume: 99 start-page: 4940 issue: 12 year: 2010 ident: 10.1002/jps.24067_bb0200 article-title: The developability classification system: Application of biopharmaceutics concepts to formulation development publication-title: J Pharm Sci doi: 10.1002/jps.22217 – volume: 23 start-page: 165 issue: 1 year: 2006 ident: 10.1002/jps.24067_bb0080 article-title: Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies publication-title: Pharm Res doi: 10.1007/s11095-005-8476-1 – volume: 345 start-page: 9 issue: 1 year: 2007 ident: 10.1002/jps.24067_bb0125 article-title: Stable drug encapsulation in micelles and microemulsions publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2007.08.057 – volume: 103 start-page: 1050 issue: 4 year: 2013 ident: 10.1002/jps.24067_bb0105 article-title: Choice of nonionic surfactant used to formulate Type IIIA self-emulsifying drug delivery systems has a pronounced influence on the degree of drug supersaturation that develops during in vitro digestion publication-title: J Pharm Sci doi: 10.1002/jps.23856 – volume: 101 start-page: 3360 issue: 9 year: 2012 ident: 10.1002/jps.24067_bb0045 article-title: Toward the establishment of standardized in vitro tests for lipid-based formulations: 1) Method parameterization and comparison of in vitro digestion profiles across a range of representative formulations publication-title: J Pharm Sci doi: 10.1002/jps.23205 – volume: 1771 start-page: 633 issue: 5 year: 2007 ident: 10.1002/jps.24067_bb0025 article-title: Comparative study on digestive lipase activities on the self emulsifying excipient Labrasol (R), medium chain glycerides and PEG esters publication-title: Biochim Biophys Acta doi: 10.1016/j.bbalip.2007.02.009 – year: 2013 ident: 10.1002/jps.24067_bb0070 – volume: 92 start-page: 2386 issue: 12 year: 2003 ident: 10.1002/jps.24067_bb0035 article-title: Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability publication-title: J Pharm Sci doi: 10.1002/jps.10511 – volume: 9 start-page: 2063 year: 2012 ident: 10.1002/jps.24067_bb0140 article-title: Lipid digestion as a trigger for supersaturation: In vitro and in vivo evaluation of the utility of polymeric precipitation inhibitors in self emulsifying drug delivery systems publication-title: Mol Pharm doi: 10.1021/mp300164u – year: 2013 ident: 10.1002/jps.24067_bb0075 – volume: 62 start-page: 63 issue: 1 year: 2010 ident: 10.1002/jps.24067_bb0195 article-title: Effects of polysorbate 80 on the in-vitro precipitation and oral bioavailability of halofantrine from polyethylene glycol 400 formulations in rats publication-title: J Pharm Pharmacol doi: 10.1211/jpp.62.01.0006 – volume: 24 start-page: 2084 issue: 11 year: 2007 ident: 10.1002/jps.24067_bb0095 article-title: Low dose lipid formulations: Effects on gastric emptying and biliary secretion publication-title: Pharm Res doi: 10.1007/s11095-007-9363-8 – volume: 10 start-page: 2601 issue: 7 year: 2013 ident: 10.1002/jps.24067_bb0165 article-title: The supersaturation tendency of drugs during intestinal processing of lipid-based formulations is greater for basic than neutral/acidic drugs publication-title: Mol Pharm doi: 10.1021/mp400035z – volume: 98 start-page: 516 issue: 2 year: 2009 ident: 10.1002/jps.24067_bb0190 article-title: Characterization and optimization of AMG 517 supersaturatable self-emulsifying drug delivery system (S-SEDDS) for improved oral absorption publication-title: J Pharm Sci doi: 10.1002/jps.21451 – volume: 65 start-page: 315 issue: 1 year: 2013 ident: 10.1002/jps.24067_bb0145 article-title: Strategies to address low drug solubility in discovery and development publication-title: Pharm Rev doi: 10.1124/pr.112.005660 – volume: 18 start-page: 333 issue: 1 year: 1967 ident: 10.1002/jps.24067_bb0180 article-title: Detergent properties of bile salts: Correlation with physiological function publication-title: Ann Rev Med doi: 10.1146/annurev.me.18.020167.002001 – volume: 99 start-page: 3522 issue: 8 year: 2010 ident: 10.1002/jps.24067_bb0110 article-title: Biorelevant media simulating fed state intestinal fluids: Colloid phase characterization and impact on solubilization capacity publication-title: J Pharm Sci doi: 10.1002/jps.22122 – volume: 30 start-page: 145 issue: 1 year: 1987 ident: 10.1002/jps.24067_bb0175 article-title: Bile salts as biological surfactants publication-title: Colloids Surf doi: 10.1016/0166-6622(87)80207-X – volume: 21 start-page: 1405 issue: 8 year: 2004 ident: 10.1002/jps.24067_bb0150 article-title: Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation publication-title: Pharm Res doi: 10.1023/B:PHAM.0000036914.22132.cc – volume: 3 start-page: 97 issue: 1 year: 2006 ident: 10.1002/jps.24067_bb0120 article-title: Development of supersaturatable self-emulsifying drug delivery system formulations for improving the oral absorption of poorly soluble drugs publication-title: Expert Opin Drug Deliv doi: 10.1517/17425247.3.1.97 – volume: 30 start-page: 2979 issue: 12 year: 2013 ident: 10.1002/jps.24067_bb0135 article-title: Lipid-based formulations and drug supersaturation: Harnessing the unique benefits of the lipid digestion/absorption pathway publication-title: Pharm Res doi: 10.1007/s11095-013-1126-0 – volume: 86 start-page: 427 issue: 3 year: 2013 ident: 10.1002/jps.24067_bb0160 article-title: Comparison of in vitro tests at various levels of complexity for the prediction of in vivo performance of lipid-based formulations: Case studies with fenofibrate publication-title: Eur J Pharm Biopharm doi: 10.1016/j.ejpb.2013.10.016 |
| SSID | ssj0006055 |
| Score | 2.3070316 |
| Snippet | The Lipid Formulation Classification System Consortium looks to develop standardized in vitro tests and to generate much-needed performance criteria for... The Lipid Formulation Classification System Consortium looks to develop standardized in vitro tests and to generate much‐needed performance criteria for... |
| SourceID | proquest pubmed crossref wiley elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2441 |
| SubjectTerms | Analgesics - chemistry Bile Acids and Salts - chemistry bioavailability Chemistry, Pharmaceutical - methods drug solubilization Excipients - chemistry Fenofibrate - chemistry Hydrogen-Ion Concentration Hypolipidemic Agents - chemistry in vitro digestion testing in vitro models LFCS Consortium lipid-based drug delivery systems Lipids - chemistry ortho-Aminobenzoates - chemistry Pharmaceutical Preparations - chemistry precipitation SEDDS Solubility supersaturation Surface-Active Agents - chemistry |
| Title | Toward the Establishment of Standardized In Vitro Tests for Lipid-Based Formulations, Part 4: Proposing a New Lipid Formulation Performance Classification System |
| URI | https://dx.doi.org/10.1002/jps.24067 https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjps.24067 https://www.ncbi.nlm.nih.gov/pubmed/24985238 https://www.proquest.com/docview/1548291019 https://www.proquest.com/docview/1549198801 |
| Volume | 103 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 0022-3549 databaseCode: DR2 dateStart: 19960101 customDbUrl: isFulltext: true eissn: 1520-6017 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0006055 providerName: Wiley-Blackwell |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1Lb9QwEMetqicuQCmPpaUaEKo4bLZ52EkMJ4q6Kj2giAbUA5IVx7ZUQNmq2T20Jz4C34Fvxifp2M6DRyshbitlorXlsf2bif0fQp4nGCIwpbMA4x8ZUFOzgKcxD5Shtc4oNaFyap_v0sMP9OiEnayRV_1dGK8PMSTc7Mxw67Wd4JVs90bR0M9n7cxuR_YmeZQw94n2_SgdhZjOBqVwDIJ6VaEw3hvevGkv-ps1f0dXt_fM75BPfav9kZMvs9VSzurLPwQd_7Nbd8ntjknhtXeiDbKmm3tkt_Ci1hdTKMc7Wu0UdqEY5a4vNsmP0p28BSRJOEDWdGktm3OEhYHjLlNxeqkVvG3g4-nyfAEldroFxGWwpbPVz2_f93EzVTBHgO7KieEfFejVQF9CYQs52JQGVIBrsn_nV1soxtsP4Kp82vNP_pFXZL9PyvlB-eYw6Eo_BLUl0iA3DjR0nlU8UVYHL0ZwDHNt9f8YNZHJwkxKyRVnteQpUqMt7ZByqSKMuZMHZL1ZNPoRAZ2laagMgpoJqeKykknOZMUjlWr0kWhCXvQ-IOpOFt1W5_gqvKBzLHBEhBuRCXk2mJ55LZDrjKa9I4kOYjycCBzr68y3e2cT3erRChtGxshxEZ-Qp8NjnPf2Y07V6MXK2fCI4-qLPXjonXRoFIbUOUMWw745V7u5teKoOHY_Hv-76Ra5hdRI_SnIbbK-PF_pJ0hmS7njpuAVZN419g |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1Lb9QwEMetUg5w4f1YKDAgVHHYbJOs8zDiwqOrbSlVRFPUC7Li2JEKKFt1dw_tiY_Ad-Cb8UmYsfPg0UqI20qZaG15bP9mYv-HsadjDBEibRIP4x_l8aqMPBGHwtMVL03CeeVrq_a5G0_3-fZBdLDCXrR3YZw-RJdwo5lh12ua4JSQ3uhVQz8dzUe0HyUX2EX6PkfT8s37XjwKQT3qtMIxDGp1hfxwo3v1vN3ob9r8HV7t7jO5yj627XaHTj6Plgs1Kk__kHT8345dY1caLIWXzo-usxVT32DrmdO1PhlC3l_Tmg9hHbJe8frkJvue28O3gDAJm4ibNrNFaUeYVbDXJCsOT42GrRo-HC6OZ5Bjr-eAxAxUPVv_-PrtFe6nGibI0E1FMfyjDB0b-HPIqJYDZTWgAFyW3Tu_2kLWX4AAW-iTjkC5R06U_RbLJ5v566nXVH_wSoJSL60sa5g0KcRYkxReiOzop4YkACNeBVXiJ0opoUVUKhEjOFJ1h1goHWDYPb7NVutZbe4yMEkc-7pCVqt8roUq1DiNVCECHRt0kmDAnrVOIMtGGZ0KdHyRTtM5lDgi0o7IgD3pTI-cHMhZRsPWk2TDMY5PJA72WeZrrbfJZgGZS4okQ0S5QAzY4-4xTn36nlPUZra0NiIQuABjD-44L-0ahVF1GiGOYd-sr53fWrmd7dkf9_7d9BG7NM3f7cidrd2399llhEjuDkWusdXF8dI8QFBbqId2Pv4EnP86Eg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1Lb9QwEMet0kqIC4_y2lJgQKjisNkmWedhOFHoqi2oimioekCy4tiW-lB21d09tCc-At-Bb9ZP0rGdB9BWQtxWykRry2P7NxP7P4S8GWKIEEmVeBj_CI_qMvJYHDJPalqqhFLtS6v2uRtvfaM7B9HBAnnf3IVx-hBtws3MDLtemwk-kXq9Ew09mkwHZjtKbpElGmN0ZYjoa6cdhZwetVLhGAU1skJ-uN6-etNmdBU2_2RXu_mM7pHvTbPdmZPjwXwmBuX5X4qO_9mv--RuDaXwwXnRA7KgqmWyljlV67M-5N0lrWkf1iDr9K7PHpJfuT16C4iSsImwafNaJukIYw17dari8FxJ2K5g_3B2OoYcOz0F5GUwtbPlxY-fG7ibShghQdf1xPCPMnRroO8gM5UcTE4DCsBF2b3zuy1k3fUHsGU-zQEo98hJsj8i-Wgz_7jl1bUfvNIgqZdqSxoqTQo2lEYIL0Ry9FNlBAAjqgOd-IkQgkkWlYLFiI2mtkPMhAww6B4-JovVuFJPCagkjn2pkdS0TyUThRimkShYIGOFPhL0yNvGB3hZ66Kb8hwn3Ck6hxxHhNsR6ZHXrenEiYFcZ9RvHInXFOPohONYX2e-2jgbr5ePKTdxZIggF7AeedU-xolvvuYUlRrPrQ0LGC6_2IMnzknbRmFMnUYIY9g362o3t5bvZHv2x8q_m74kt7NPI_5le_fzM3IHCZK6E5GrZHF2OlfPkdJm4oWdjZfJEjjB |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Toward+the+establishment+of+standardized+in+vitro+tests+for+lipid-based+formulations%2C+part+4%3A+proposing+a+new+lipid+formulation+performance+classification+system&rft.jtitle=Journal+of+pharmaceutical+sciences&rft.au=Williams%2C+Hywel+D&rft.au=Sassene%2C+Philip&rft.au=Kleberg%2C+Karen&rft.au=Calderone%2C+Marilyn&rft.date=2014-08-01&rft.issn=1520-6017&rft.eissn=1520-6017&rft.volume=103&rft.issue=8&rft.spage=2441&rft_id=info:doi/10.1002%2Fjps.24067&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-3549&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-3549&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-3549&client=summon |